Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.40 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.40 |
| ▸ | MASP2 | O00187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19324126 | 0.87 | TRPV1 (0.42) | TRPV1EGFRPTGESSCN10ASCN5A | |
| SCHEMBL16355448 | 0.85 | SCN10A (0.41) | EGFRSCN10ASCN5ANLN | |
| SCHEMBL20900023 | 0.83 | EGFR (0.46) | EGFRSCN10ASCN5ANLN | |
| SCHEMBL20900024 | 0.83 | EGFR (0.46) | EGFRSCN10ASCN5ANLN | |
| SCHEMBL18480825 | 0.83 | MASP2 (0.55) | MASP2 | |
| SCHEMBL20900140 | 0.83 | MASP2 (0.55) | MASP2 | |
| Hydrochloric Acid SCHEMBL18438992 | 0.81 | MASP2 (0.53) | MASP2 | |
| SCHEMBL16355449 | 0.81 | PTGES (0.43) | TRPV1EGFRPTGES | |
| SCHEMBL10254066 | 0.81 | HPGDS (0.49) | SCN10ASCN5ANLN | |
| SCHEMBL16355444 | 0.81 | PTGES (0.43) | TRPV1EGFRPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | TRPV1 3957/4885EGFR 1038/4885PTGES 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.